

## PRIOR AUTHORIZATION POLICY

**POLICY:** Antiepileptics – Fintepla Prior Authorization Policy

- Fintepla® (fenfluramine oral solution – Zogenix)

**REVIEW DATE:** 04/13/2022

---

### OVERVIEW

Fintepla, a serotonin 5-hydroxytryptamine subtype 2 (5-HT<sub>2</sub>) agonist, is indicated in patients ≥ 2 years of age for the treatment of **seizures associated with:**

- **Dravet syndrome.**
- **Lennox-Gastaut syndrome.**

### Disease Overview

Dravet syndrome is a rare genetic epileptic encephalopathy (dysfunction of the brain) marked with frequent and/or prolonged seizures.<sup>2,3</sup> It is estimated that 1 out of 15,700 infants born in the US are affected with Dravet syndrome. The seizures generally begin in the first year of life in an otherwise healthy infant. Affected individuals can develop many seizure types: myoclonic, tonic-clonic, absence, atypical absence, atonic, focal aware or impaired awareness (previously called partial seizures), and status epilepticus.<sup>3</sup> As the seizures continue, most of the children develop some level of developmental disability and other conditions associated with the syndrome. Two or more antiepileptic drugs (AEDs) are often needed to control the seizures; most of the seizures are refractory to medications. The goals of treatment are cessation of prolonged convulsions, reductions in overall seizure frequency, and minimization of treatment side effects.<sup>4,5</sup> Some patients respond to the ketogenic diet and/or vagus nerve stimulation.

Lennox-Gastaut syndrome, a severe epileptic and developmental encephalopathy, is associated with a high rate of morbidity and mortality.<sup>6,7</sup> Lennox-Gastaut syndrome most often begins between 3 and 5 years of age.<sup>6,9</sup> Affected children experience several different types of seizures, most commonly atonic seizures (sudden loss of muscle tone and limpness) and tonic seizures.<sup>6,9</sup> The three main forms of treatment of Lennox-Gastaut syndrome are AEDs, dietary therapy (typically the ketogenic diet), and device/surgery (e.g., vagus nerve stimulation, corpus callostomy).<sup>9</sup> None of the therapies are effective in all cases of Lennox-Gastaut syndrome and the disorder has proven particularly resistant to most therapeutic options.

### Guidelines

Fintepla is not mentioned in the current treatment recommendations.

### Dravet Syndrome

At this time, there are three drugs approved for the treatment of seizures associated with Dravet syndrome: Diacomit® (stiripentol capsules, powder for oral suspension), Epidiolex® (cannabidiol oral solution), and Fintepla.<sup>1,10</sup> An expert panel considers valproic acid and clobazam to be the first-line treatments for Dravet syndrome.<sup>4</sup> If seizure control is suboptimal, Diacomit and topiramate are second-line treatments. Ketogenic diet is moderately effective and can also be considered second-line. The Dravet Foundation states that Diacomit, Epidiolex, and Fintepla are considered first-line agents for the treatment of Dravet syndrome.<sup>2</sup> If control is still inadequate, other therapies to consider are clonazepam, levetiracetam, and zonisamide.<sup>2,4</sup> Sodium channel blockers (e.g., carbamazepine, oxcarbazepine, lamotrigine, and phenytoin) can worsen seizures in Dravet syndrome. Additionally, vigabatrin and tiagabine may increase the frequency of myoclonic seizures and should be avoided.

### Lennox-Gastaut Syndrome

04/13/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Currently, the FDA-approved drugs for this condition are Fintepla, clobazam, Banzel® (rufinamide tablet, oral suspension), Epidiolex, felbamate, lamotrigine, and topiramate. Despite the lack of level I or level II evidence, valproic acid remains a mainstay in treatment.<sup>8,9,12</sup> If valproic acid does not provide adequate seizure control, which is almost always the case, lamotrigine should be added as the first adjunctive therapy.<sup>7</sup> If the combination regimen of valproic acid and lamotrigine does not provide adequate control, then Banzel should be initiated and either valproic acid or lamotrigine should be discontinued. If seizure control is still not achieved, the next adjunctive therapies to consider are topiramate, clobazam, and felbamate. There is limited evidence for the use of levetiracetam, zonisamide, and Fycompa® (perampanel tablet, oral suspension). Where possible, no more than two AEDs should be used concomitantly; use of multiple AEDs raise the risk of side effects and/or drug-drug interactions.

### **POLICY STATEMENT**

Prior Authorization is recommended for prescription benefit coverage of Fintepla. Because of the specialized skills required for evaluation and diagnosis of patients treated with Fintepla as well as the monitoring required for adverse events and long-term efficacy, initial approval requires Fintepla to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for the duration noted below.

**Automation:** None.

### **RECOMMENDED AUTHORIZATION CRITERIA**

Coverage of Fintepla is recommended in those who meet the following criteria:

#### **FDA-Approved Indications**

- 1. Dravet Syndrome.** Approve if the patient meets ONE the following criteria (A or B):
  - A) Initial Therapy.** Approve for 1 year if the patient meets the following (i, ii, and iii):
    - i.** Patient is  $\geq 2$  years of age; AND
    - ii.** Patient meets ONE of the following (a or b):
      - a)** Patient has tried or is concomitantly receiving at least two other antiepileptic drugs; OR  
Note: Examples of other antiepileptic drugs include valproic acid, topiramate, clonazepam, levetiracetam, zonisamide.
      - b)** Patient has tried or is concomitantly receiving one of clobazam, Epidiolex or Diacomit; AND
    - iii.** Fintepla is prescribed by or consultation with a neurologist; OR
  - B) Patient is Currently Receiving Fintepla.** Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.
- 2. Lennox-Gastaut Syndrome.** Approve if the patient meets ONE of the following criteria (A or B):
  - A) Initial Therapy.** Approve for 1 year if the patient meets the following criteria (i, ii, and iii):
    - i.** Patient is  $\geq 2$  year of age; AND
    - ii.** Patient has tried or is concomitantly receiving at least two other antiepileptic drugs; AND  
Note: Examples of other antiepileptic drugs include Banzel, clobazam, Epidiolex, felbamate, lamotrigine, topiramate, valproic acid, levetiracetam, zonisamide, Fycompa, vigabatrin.
    - iii.** The medication is prescribed by or in consultation with a neurologist.
  - B) Patient is Currently Receiving Fintepla.** Approve for 1 year if the patient is responding to therapy (e.g., reduced seizure severity, frequency, and/or duration) as determined by the prescriber.

### CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Fintepla is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

### REFERENCES

1. Fintepla® oral solution [prescribing information]. Emeryville, CA: Zogenix; March 2022.
2. Dravet Foundation – Dravet Syndrome. Available at: <https://www.dravetfoundation.org/what-is-dravet-syndrome/>. Accessed on July 11, 2021.
3. Shafer PO. Epilepsy Foundation – Dravet Syndrome. Updated August 2020. Available at: <http://www.epilepsy.com/learn/types-epilepsy-syndromes/dravet-syndrome>. Accessed on July 11, 2021.
4. Wirrell EC, Laux L, Donner, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American Consensus Panel. *Pediatr Neurol*. 2017;68:18-34.
5. Knupp KG1, Wirrell EC. Treatment Strategies for Dravet Syndrome. *CNS Drugs*. 2018;32(4):335-350.
6. Sirven JI, Shafer PO. Epilepsy Foundation – Lennox-Gastaut Syndrome. Updated February 2020. Available at: <https://www.epilepsy.com/learn/types-epilepsy-syndromes/lennox-gastaut-syndrome-lgs>. Accessed on January 31, 2022.
7. Cross JH, Auvin S, Falip M, et al. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. *Front Neurol*. 2017;8:505.
8. Ostendorf AP, Ng YT. Treatment-resistant Lennox-Gastaut syndrome: therapeutic trends, challenges, and future directions. *Neuropsych Dis Treatment*. 2017;13:1131-1140.
9. Wheless JW. National Organization for Rare Diseases (NORD) – Lennox-Gastaut syndrome. Available at: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/#standard-therapies>. Accessed on January 31, 2022..
10. Diacomit® capsules, powder for oral suspension [prescribing information]. Redwood City, CA: Bicodex; August 2018.
11. Lennox-Gastaut Syndrome Foundation – Lennox-Gastaut Syndrome. Available at: <https://www.lgsfoundation.org/about-lgs-2/what-is-lennox-gastaut-syndrome/>. Accessed on April 7, 2022.
12. Wheless JW. Lennox-Gastaut syndrome. Available at: <https://rarediseases.org/rare-diseases/lennox-gastaut-syndrome/>. Accessed on April 7, 2022.